The earnings report itself is overshadowed by the recent dilutive offering. Key near-term catalyst is the EULAR data June 3-6 (complete SLE/SSc data) which could drive a re-rating. Until then, expect pressure from increased share count and cash burn. Monitor for any guidance on pivotal trial timelines.
Price Chart
Executive Summary
Cabaletta Bio reported Q1 2026 net loss of $43.5M (EPS -$0.39, beating consensus of -$0.41 by ~5%) with cash of $116.6M, supplemented by a recent $150M dilutive offering. The earnings were overshadowed by pipeline updates, positive PC-free rese-cel data at ASGCT and progressing registrational myositis trial, but the 51% share dilution from the May 2026 offering and rising operating losses weigh on near-term sentiment.
Key Financial Metrics
Key Facts
- Net loss widened to $43.5M in Q1 2026 from $35.9M in Q1 2025 (21% increase).
- R&D expenses rose 29% to $37.4M, reflecting clinical trial expansion.
- Cash, equivalents, and investments fell to $116.6M from $133.6M at year-end 2025.
- Recent $150M registered direct offering at $2.90/share diluted existing shareholders by ~51%.
- Clinical data: PC-free rese-cel showed drug-free responses in half of PV patients at 6 months; registrational myositis trial advancing.
- Cash runway extended into mid-2027 post offering, but burn rate is accelerating.
Financial Impact
EPS beat consensus by $0.02 (4.9%), but net loss increased $7.6M YoY; 51% dilution from recent offering reduces per-share value.
Risk Factors
- Further dilution if additional capital raises are needed before BLA submission.
- Clinical trial failure or regulatory setbacks for rese-cel.
- Cash burn exceeding projections; need for additional financing.
- Low stock price and reduced liquidity post-offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000025 |
| Document: caba-20260514.htm | 0001759138-26-000025 |
| Document: 0001759138-26-000025-index-headers.html | 0001759138-26-000025 |
| Document: 0001759138-26-000025-index.html | 0001759138-26-000025 |
| Document: 0001759138-26-000025.txt | 0001759138-26-000025 |
| 8-K Data (Synthetic) | 0001759138-26-000025 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers